Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis

Charles Y C Pak, Roy D. Peterson, John Poindexter

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Purpose: We determine if potassium citrate treatment stabilizes spinal bone density among patients with recurrent calcium oxalate nephrolithiasis. Materials and Methods: We studied a group of 16 men and 5 women with stones taking potassium citrate from 11 to 120 months. They represented all patients from the Stone Clinic who took potassium citrate alone for at least 11 months. L2-L4 bone mineral density data before and after potassium citrate treatment were retrieved retrospectively and analyzed. Results: In the combined group L2-L4 bone mineral density increased significantly by 3.1% over mean duration of 44 months. Z score, corrected for age matched normal values, increased significantly by 3.8%. Urinary pH, citrate and potassium increased significantly during treatment but urinary calcium did not change. Conclusions: Potassium citrate, a commonly used drug for the prevention of recurrent nephrolithiasis, may avert age dependent bone loss. Spinal bone density increased in most patients when it normally decreases.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
JournalJournal of Urology
Issue number1
StatePublished - 2002


  • Bone density
  • Calculi
  • Potassium citrate

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis'. Together they form a unique fingerprint.

Cite this